Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 29, 2026)


ROCO:7427 Great Novel Therapeutics Biotech & Medicals ROCO:7427
52 GF Score
Price NT$38.55
GF Value NT$25.57
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Great Novel Therapeutics Biotech & Medicals Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Great Novel Therapeutics Biotech & Medicals's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

ROCO:7427 vs VRTX, REGN, ALNY: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's Margin of Safety % (DCF FCF Based) falls into.


ROCO:7427
52GF Score
Great Novel Therapeutics Biotech & Medicals ROCO:7427
Margin of Safety % (DCF FCF Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Overvalued in 2026?

Based on GuruFocus' analysis, Great Novel Therapeutics Biotech & Medicals stock appears to be overvalued. The current stock price of NT$38.55 is trading 50.8% above its estimated GF Value™ of NT$25.57. GuruFocus considers Great Novel Therapeutics Biotech & Medicals to be Significantly Overvalued.

Key valuation signals for ROCO:7427:

  • Margin of Safety % (DCF FCF Based): N/A
  • GF Value™: NT$25.57 vs. price of NT$38.55 (50.8% above fair value)
  • GF Score™: 52/100 with 3 warning signs

No single metric tells the full story. See the ROCO:7427 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Great Novel Therapeutics Biotech & Medicals Business Description

Address No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.
52GF Score

Get the complete analysis for ROCO:7427

Margin of Safety % (DCF FCF Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$38.55
Price
NT$25.57
GF Value